Chinese Journal of Pharmacovigilance ›› 2017, Vol. 14 ›› Issue (4): 222-225.
Previous Articles Next Articles
HAO Li-pan, WANG Shu-ling
Received:
2017-07-05
Revised:
2017-07-05
Online:
2017-04-20
Published:
2017-07-05
CLC Number:
HAO Li-pan, WANG Shu-ling*. Research on the Management of Waste Drugs Based on Extended Producer Responsibility[J]. Chinese Journal of Pharmacovigilance, 2017, 14(4): 222-225.
Add to citation manager EndNote|Ris|BibTeX
[1] 环境保护部.国家危险废物名录[EB/OL].(2016-06-14)[2017-03-29]. http://www.zhb.gov.cn/gkml/hbb/bl/201606/t20160621_354852.htm. [2] GB/T 18354-2006, 中华人民共和国国家标准:物流术语[S]. [3] 王君平.目前我国每个家庭过期药品达200多粒:过期药都去哪了[N]. 人民日报,2014-04-09 (02). [4] 侯崇智、杨文娟. 我国超八成家庭没有清理过期药品[N]. 人民网, 2014-03-20 (13). [5] 陈世吉,蔡金炼, 柯福志. 一起因销毁过期药品污染环境而引起中毒的事故调查[J]. 海峡预防医学杂志,2005, 11(3):42-42. [6] 肖纯,左雪莲. 我国药品逆向物流发展的障碍及对策分析[J]. 物流技术, 2006, (10): 7-9. [7] 罗凯,徐逸桥. 美国药品供应链的创新[J]. 物流, 2008, (5): 14-15. [8] 广药白云山.中国家庭过期药品回收白皮书(2004-2014年)[Z]. 广州:广药集团白云山, 2015. [9] 雷婷,叶桦. 家庭废弃药品的潜在危害和回收成本分析[J]. 中国药事, 2008, 22(7): 445-446. [10] 黎秋玲,庞倩影. 家用剩余药品怎样处理 过期药品有害勿随意扔掉[N]. 北京晚报, 2014-03-19 (4). [11] Thomas, Lindhqvist, Reid Lisfest. Can we take the concept of individual producer responsibility from theory to practice?[J]. Journal of Industrical Ecology, 2010, 7(2):3-6. [12] 魏洁. 企业逆向物流制度与模式[M]. 北京:人民邮电出版社, 2009: 12-13. [13] 国务院办公厅.国务院办公厅关于印发生产者责任延伸制度推行方案的通知[EB/OL].(2017-01-03)[2017-03-29].http://www.gov.cn/zhengce/content/2017-01/03/content_5156043.htm. [14] 刘婷. 基于三方进化博弈的药品回收逆向物流分析[J]. 物流科技, 2014, 37(2): 115-120 [15] 张亚轩. 基于逆向物流的过期药品回收演化博弈研究[D].2015: 56-57. |
[1] | ZHAO Jie, GAO Minge, CHANG Hong, FAN Huixia. Pathogen Distribution, Drug Resistance and Drug Use in Neonates with Necrotizing Enterocolitis Complicated with Sepsis [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 909-913. |
[2] | QI Yujie, WANG Xin, ZHANG Jiahui, MA Enlong, GENG Xingchao. Research Progress in Integration Sites for Cellular and Gene Therapy Products [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 721-727. |
[3] | LI Dong, SONG Yana, WANG Ligang, BIAN Rongrong, ZHAO Yan. Considerations for Establishing National Sentinel Hospitals for Medical Device Adverse Event Monitoring [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 780-785. |
[4] | ZHU Huijuan, REN Jingtian. Safety Risks of Human Rabies Immunoglobulin [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 786-789. |
[5] | LI Qiurong, FU Miaoqing, ZHOU Baishui, LI Cui, XIAO Xiaotong, YU Yuping, DENG Lu. Mining of Real-World ADR Signals Related to Cefradine for Injection in 268 Cases [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 790-793. |
[6] | LI Can, LIU Lehuan, CHEN Xia, QU Jianbo. Pharmacy of Chinese Medicine Compound Preparations Based on Human Experiences [J]. Chinese Journal of Pharmacovigilance, 2025, 22(5): 564-569. |
[7] | YANG Xuyun, SUN Yang, TIAN Chunhua, HU Zengyao. A National Pharmacovigilance Management System in a New Era [J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 276-281. |
[8] | LIU Ying, XIONG Shunyu, XIONG Huiyu, CAI Fei, XU Mengdan, WANG Qing, REN Wei, XU Yan. Methods for Assessment of MAH Compliance with GVP [J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 282-285. |
[9] | ZHU Lan, SHAO Bo, ZHU Yan, DAI Jie, ZHONG Shiqi. Current Progress and Considerations in Updating the Safety Information in Labels of Chinese Traditional Patent Medicines [J]. Chinese Journal of Pharmacovigilance, 2025, 22(2): 188-192. |
[10] | LI Wenlong, JIA Juanjuan, HUANG Haiwei, YAO Jing, ZHANG Chunqing, WANG Yan, ZHANG Hui. Developments and Prospects of Radiopharmaceuticals in China [J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 37-42. |
[11] | SONG Fuyu, CAO Yi. Establishment of Key Performance Indicators for Drug Inspection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(12): 1411-1414. |
[12] | ZHAO Peipei, WEN Baoshu. Regulation of cellular and gene therapies at home and abroad [J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1019-1024. |
[13] | YANG Le, SHAN Lianlian, WANG Yali, YAN Shunhua, ZHOU Gang, CHEN Jia, WEI Feng. Quality standard for licorice of different sources [J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1025-1028. |
[14] | SUN Yixin, NIE Xiaolu, WANG Xiaoling, GUO Peng. Comparative research on active post-marketing drug safety surveillance systems worldwide based on real-world data [J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 892-899. |
[15] | WEI Fenfang, WU Wenyu, LI Limin, TANG Biyu, WU Jianru. Foreign methods for benefit-risk assessment of pharmaceutical products [J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 900-905. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||